KiMi Business Demand Increases, Revenue to Rise Quarterly

Reported about 1 year ago

KiMi General Manager Jiang Junqi stated on July 4, 2024, that the company's deep research services, clinical testing, and CDMO core business, combined with resources from subsidiary Lester and other factors, have shown gradual benefits from diversified transformation and upgrades. Anticipating increased demand for LDTs (Laboratory Developed Tests) services and NGS (Next-Generation Sequencing) business, as well as contributions from new Thermo exclusive agencies and CDMO performance, KiMi expects revenue to rise quarter by quarter in the second half of the year, with annual revenue growth starting in the double digits. The company's revenue mix currently consists of approximately 70% from scientific research services, 25% from clinical testing, and 5% from CDMO. With an increase in NGS testing demand in the second half of the year, the revenue is expected to accelerate further.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis